J. Epstein

发表

Advances in Biology and Therapy of Multiple Myeloma

Bart Barlogie, Joth Jacobson, R. Bataille, 2013, Springer New York.

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Yongsheng Huang, J. Stewart, F. Zhan, 2006, Blood.

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

F. Zhan, B. Barlogie, J. Shaughnessy, 2010, Blood.

The molecular classification of multiple myeloma.

John Crowley, Simona Colla, Bart Barlogie, 2006, Blood.

Biomarkers that Discriminate Multiple Myeloma Patients with or without Skeletal Involvement Detected Using SELDI-TOF Mass Spectrometry and Statistical and Machine Learning Tools

L. Suva, S. Bhattacharyya, J. Epstein, 2006, Disease markers.

Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen

J. Woodliff, J. Epstein, R. Sanderson, 1993 .

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?

M. Kumar, B. Barlogie, G. Morgan, 2019, Theranostics.

Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells.

J. Woodliff, J. Epstein, M. Petrucci, 1993, Blood.

Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells

J. Woodliff, J. Epstein, M. Petrucci, 1993 .

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

Caleb K. Stein, O. Stephens, B. Barlogie, 2017, Nature Communications.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.

J. Magaud, X. Thomas, E. Archimbaud, 1998, Leukemia & lymphoma.

2Biological aspects of multiple myeloma

B. Barlogie, J. Epstein, R. Hoover, 1995 .

Interleukin-6 prevents dexamethasone-induced myeloma cell death.

B. Barlogie, I. Grigorieva, J. Epstein, 1994, Blood.

Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population.

X. Thomas, J. Epstein, H. Xiao, 1992, Current topics in microbiology and immunology.

Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement.

B. Barlogie, J. Katzmann, J. Epstein, 1988, Blood.

Differentiation stage of myeloma plasma cells: biological and clinical significance

B. Barlogie, G. Morgan, F. Prósper, 2017, Leukemia.

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

B. Barlogie, A. Órfão, N. Puig, 2016, Blood.

Cancer and the Microenvironment

B. Barlogie, J. Epstein, M. Cottler-Fox, 2004, Cancer Research.

Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations

B. Barlogie, J. Epstein, S. Yaccoby, 1998 .

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008, Cancer.

Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease

B. Barlogie, G. Morgan, M. Zangari, 2017, American journal of hematology.

The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable

E. Sausville, B. Barlogie, K. Anderson, 2003 .

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008, Blood.

Plasma cell myeloma--new biological insights and advances in therapy.

B. Barlogie, J. Epstein, R. Alexanian, 1989, Blood.

Soluble syndecan-1 promotes growth of myeloma tumors in vivo.

J. Epstein, R. Sanderson, S. Yaccoby, 2002, Blood.

Myeloma phenotype: clues to disease origin and manifestation.

J. Epstein, Joshua Epstein, 1992, Hematology/oncology clinics of North America.

Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen.

J. Woodliff, J. Epstein, R. Sanderson, 1993, Blood.

Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes

B. Barlogie, G. Morgan, M. Zangari, 2018, British journal of haematology.

Myeloma Bone Disease

J. Epstein, R. Sanderson, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

J. Stewart, B. Barlogie, J. Shaughnessy, 2014, Blood.

PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias

B. Barlogie, E. Anaissie, G. Tricot, 2006 .

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma.

O. Stephens, V. Raj, A. Vangsted, 2014, Blood.

Heparanase promotes the spontaneous metastasis of myeloma cells to bone.

L. Suva, Y. Huang, P. Kussie, 2004, Blood.

Paul bone Heparanase promotes the spontaneous metastasis of myeloma cells to

L. Suva, Y. Huang, P. Kussie, 2004 .

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, Blood.

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease

B. Barlogie, J. Shaughnessy, J. Epstein, 2013, American journal of hematology.

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood cancer journal.

The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.

J. Epstein, S. Yaccoby, 1999, Blood.

β2‐microglobulin as a negative growth regulator of myeloma cells

B. Barlogie, Zhongkui Li, J. Epstein, 2002, British journal of haematology.

Genotypic and phenotypic diversity of plasma cell myeloma

B. Barlogie, J. Epstein, R. Alexanian, 1988 .

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

T. Willis, B. Barlogie, G. Morgan, 2017, Haematologica.

Myeloma interacts with the bone marrow microenvironment  to induce osteoclastogenesis and is dependent on osteoclast activity

B. Barlogie, J. Epstein, R. Pearse, 2002, British journal of haematology.

IP(3), IP(3) receptor, and cellular senescence.

S. Goldstein, M. Zaidi, M. S. Huang, 2000, American journal of physiology. Renal physiology.

Mitogen-Activated Protein Kinase p38 Immature Dendritic Cells: Involvement of of Lipopolysaccharide on In Vitro Generation Novel and Detrimental Effects of

J. Epstein, Siqing Wang, J. Qian, 2003 .

Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.

J. Epstein, R. Sanderson, S. Yaccoby, 2000, Blood.

Deletion of the retinoblastoma gene in multiple myeloma.

B. Barlogie, G. Tricot, J. Sawyer, 1994, Leukemia.

Myeloma stem cell phenotype. Implications for treatment.

J. Epstein, Joshua Epstein, 1997, Hematology/oncology clinics of North America.

Multiple myeloma--recent developments in molecular and cellular biology.

B. Barlogie, J. Epstein, R. Hoover, 1995, Current topics in microbiology and immunology.

DNA Flow Cytometry and Metaphase Cytogenetics Can Predict Progression of Asymptomatic Monoclonal Gammopathies (AMG) to Symptomatic Multiple Myeloma (MM).

B. Barlogie, M. Dhodapkar, J. Epstein, 2012 .

Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma.

I. Pastan, B. Barlogie, D. Fitzgerald, 1992, Blood.

High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH.

B. Barlogie, J. Shaughnessy, G. Tricot, 2000, Blood.

Clonal Growth of Leukaemic Cells In Vitro

H. Preisler, J. Epstein, 1981, Cell and tissue kinetics.

High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance

Erich A. Peterson, O. Stephens, B. Barlogie, 2015 .

Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2

J. Crowley, B. Barlogie, J. Shaughnessy, 2008 .

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, British journal of haematology.

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.

B. Barlogie, J. Epstein, F. van Rhee, 2011, Experimental hematology.

Myc/max family of transcription factors and bcl-2 are involved in drug-induced apoptosis of myeloma cells.

B. Barlogie, D. Siegel, J. Epstein, 1997, Current topics in microbiology and immunology.

detected by multiprobe interphase FISH High incidence of chromosome 13 deletion in multiple myeloma

B. Barlogie, G. Tricot, E. Tian, 2013 .

Research on Cellular Senescence: Present and Future Directions

W. Choy, J. Epstein, J. Littlefield, 1977 .

Glutamine Enhances Selectivity of Chemotherapy Through Changes in Glutathione Metabolism

J. Epstein, V. Klimberg, J. Woodliff, 1995, Annals of surgery.

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

F. Zhan, B. Barlogie, J. Shaughnessy, 2007, Clinical Cancer Research.

Markers of multiple hematopoietic-cell lineages in multiple myeloma.

J. Epstein, H. Xiao, X. Y. He, 1990, The New England journal of medicine.

Prediction of response of acute nonlymphocytic leukaemia to therapy with ‘high dose’ cytosine arabinoside

R. Larson, R. Priore, K. Rai, 1984, British journal of haematology.

Prediction of cytogenetic abnormalities with gene expression profiles.

O. Stephens, B. Barlogie, J. Shaughnessy, 2012, Blood.

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

B. Barlogie, G. Morgan, E. Tian, 2014, Blood.

Curing Multiple Myeloma (MM) with Total Therapy (TT)

B. Barlogie, G. Morgan, M. Zangari, 2014 .

Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoformycin.

J. Epstein, D. Kennedy, P. Bealmear, 1986, Experimental hematology.

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2009, Blood.

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

O. Stephens, B. Barlogie, J. Shaughnessy, 2008, Blood.

Human Placenta‐Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone

B. Barlogie, J. Shaughnessy, J. Epstein, 2011, Stem cells.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients

D. Campana, B. Barlogie, C. Rooney, 2015, Journal of immunotherapy.

Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients

D. Campana, B. Barlogie, C. Rooney, 2012 .

Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells.

J. Epstein, B. J. Chen, Bangzheng Chen, 1996, Blood.

A Comparison of Two Methods for Determining the Sensitivity of Human Myeloid Colony‐forming Units to Cytosine Arabinoside

H. Preisler, J. Epstein, Harvey D. Preisler, 1981, British journal of haematology.

Effects of cytosine arabinoside on unseparated bone marrow and peripheral blood cells and on specimens enriched for myeloblasts and promyelocytes.

H. Preisler, Y. Rustum, J. Epstein, 1980, Experimental hematology.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

John Crowley, Pingping Qu, Bart Barlogie, 2011, Blood.

IRF4 addiction in multiple myeloma

L. Staudt, Xin Yu, J. Powell, 2008, Nature.

Effects of cytosine arabinoside on DNA synthesis and the clonogenicity of RF/UN murine myeloid leukemia cells.

H. Preisler, J. Epstein, 1980, Experimental hematology.

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

B. Barlogie, E. Tian, D. Johann, 2014, Blood.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

O. Stephens, B. Barlogie, G. Morgan, 2017, Nature Communications.

Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat

B. Barlogie, G. Morgan, J. Epstein, 2015, BMC Bioinformatics.

The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Hongwei Xu, Wei Xiong, Simona Colla, 2007, Blood.

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes

B. Barlogie, E. Tian, J. Sawyer, 2014, Genes, chromosomes & cancer.

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2017, The Lancet.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Erich A. Peterson, Caleb K. Stein, O. Stephens, 2016, Blood.

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

G. Morgan, B. Walker, F. Davies, 2018, BMC Cancer.

MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.

B. Barlogie, G. Morgan, F. Davies, 2016, Blood.

The Esterase Activity in Megaloblasts, Leukaemic and Normal Haemopoietic Cells

J. Epstein, L. Rozenszajn, M. Leibovich, 1968, British journal of haematology.

Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.

B. Barlogie, D. Siegel, J. Epstein, 1999, Blood.

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, British journal of haematology.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma

B. Barlogie, B. Williams, Y. Qiang, 2013, PloS one.

Characterization of Wnt/β‐catenin signalling in osteoclasts in multiple myeloma

B. Barlogie, Y. Qiang, J. Epstein, 2010, British journal of haematology.

P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.

J. Epstein, H. Xiao, B. K. Oba, 1989, Blood.

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2020, Blood Cancer Journal.

Glucocorticoid-Induced Apoptosis by Bcl-2 B in the Rescue of Multiple Myeloma Cells From κ Role of NF-

B. Barlogie, D. Siegel, J. Epstein, 2013 .

Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia

R. Larson, G. Browman, H. Preisler, 2004, Cancer Chemotherapy and Pharmacology.

Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.

L. Booker, G. Browman, H. Preisler, 1984, European journal of cancer & clinical oncology.

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

J Shaughnessy, B. Barlogie, J. Shaughnessy, 2001, Blood.

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

B. Barlogie, G. Morgan, E. Tian, 2016, Clinical Cancer Research.

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

B. Barlogie, D. Johann, J. Sawyer, 2013, Blood.

in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities,

B. Barlogie, J. Shaughnessy, S. Jagannath, 2013 .

study of 169 patients single-agent thalidomide: identification of prognostic factors in a phase 2 Extended survival in advanced and refractory multiple myeloma after

B. Barlogie, J. Shaughnessy, N. Munshi, 2013 .

other imaging techniques and prognostic factors in multiple myeloma F18-fluorodeoxyglucose positron emission tomography in the context of

J. Shaughnessy, R. Walker, J. Epstein, 2011 .

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

John Crowley, Erik Rasmussen, Bart Barlogie, 2006, Blood.

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression.

F. Zhan, B. Barlogie, J. Shaughnessy, 2003, Blood.

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2000, Blood.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1999, Blood.

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

O. Stephens, B. Barlogie, J. Shaughnessy, 2012, Blood.

Going with the flow, and beyond, in myeloma.

B. Barlogie, J. Shaughnessy, J. Epstein, 2008, Blood.

Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells

J. Woodliff, J. Epstein, A. Waage, 2000, British journal of haematology.

Biology and therapy of multiple myeloma in 1996.

B. Barlogie, S. Jagannath, N. Munshi, 1997, Seminars in hematology.

Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival

F. Zhan, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Consequences of interactions between the bone marrow stroma and myeloma.

J. Epstein, S. Yaccoby, 2003, The hematology journal : the official journal of the European Haematology Association.

Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

B. Barlogie, J. Epstein, S. Yaccoby, 1998, Blood.

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

M. Kumar, B. Barlogie, G. Morgan, 2018, Leukemia.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Caleb K. Stein, H. Goldschmidt, B. Barlogie, 2017, Blood.

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, British journal of haematology.

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis

Caleb K. Stein, B. Barlogie, E. Tian, 2014, Oncotarget.

Novel and Detrimental Effects of Lipopolysaccharide on In Vitro Generation of Immature Dendritic Cells: Involvement of Mitogen-Activated Protein Kinase p38 1

J. Epstein, Jin Xie, Siqing Wang, 2003, The Journal of Immunology.

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.

Michael L. Wang, F. Zhan, J. Shaughnessy, 2007, Blood.

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120)

J. Crowley, B. Barlogie, G. Morgan, 2016, Blood Cancer Journal.

Proteasome inhibitors and bone disease.

B. Barlogie, J. Shaughnessy, Y. Qiang, 2012, Seminars in hematology.

cell involvement Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B

B. Barlogie, J. Katzmann, J. Epstein, 2011 .

The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.

I. Grigorieva, X. Thomas, J. Epstein, 1998, Experimental hematology.

DKK 1 as a universal myeloma antigen DKK 1 IS A WIDELY EXPRESSED AND POTENT TUMOR-ASSOCIATED ANTIGEN IN MULTIPLE MYELOMA

Michael L. Wang, F. Zhan, J. Shaughnessy, 2007 .

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

J. Crowley, B. Barlogie, E. Tian, 2016, Blood Cancer Journal.

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2008, Leukemia.

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

J. Crowley, B. Barlogie, G. Morgan, 2015, Haematologica.

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

J. Michaeli, J. Epstein, R. Pearse, 2001, Proceedings of the National Academy of Sciences of the United States of America.

B. Barlogie, J. Epstein, J. Dedman, 1988, Blood.

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

M. Kumar, B. Barlogie, G. Morgan, 2018, Blood.

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma

G. Morgan, B. Walker, F. Davies, 2018, BMC Cancer.

Curing myeloma at last: defining criteria and providing the evidence.

B. Barlogie, G. Morgan, J. Epstein, 2014, Blood.

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

B. Barlogie, G. Morgan, G. Tricot, 2019, Blood.

The Clinical Impact of Macrofocal Disease in Multiple Myeloma Differs Between Presentation and Relapse

B. Barlogie, G. Morgan, M. Zangari, 2016 .

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

B. Barlogie, G. Tricot, R. Walker, 2006, Haematologica.

The SCID-hu myeloma model.

J. Epstein, S. Yaccoby, 2005, Methods in molecular medicine.

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma

Caleb K. Stein, B. Barlogie, G. Morgan, 2015, Leukemia.

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012, Clinical Cancer Research.

Multiple myeloma: biology and therapy

B. Barlogie, J. Epstein, 2005, Journal of Cancer Research and Clinical Oncology.

Genotypic and phenotypic characteristics of multiple myeloma

B. Barlogie, J. Epstein, R. Alexanian, 1988, Hematological oncology.

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics

B. Barlogie, E. Anaissie, J. Haessler, 2007, British journal of haematology.

The Arkansas approach to therapy of patients with multiple myeloma.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2007, Best practice & research. Clinical haematology.

Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma

B. Barlogie, J. Shaughnessy, E. Tian, 2017, Leukemia.

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2012, Leukemia.

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008, Blood.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.

B. Barlogie, J. Shaughnessy, L. Suva, 2007, Blood.

Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

MRI-Detectable Focal Lesions (FL) in Multiple Myeloma (MM) at Relapse Frequently Involve Novel Sites Not Involved at Diagnosis.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2004 .

Myeloma and bone disease: "the dangerous tango".

R. Walker, J. Epstein, 2006, Clinical advances in hematology & oncology : H&O.

Antimyeloma efficacy of thalidomide in the SCID-hu model.

B. Barlogie, J. Epstein, S. Yaccoby, 2002, Blood.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

Pingping Qu, Bart Barlogie, Antje Hoering, 2017, Haematologica.

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

B. Barlogie, D. Johann, J. Epstein, 2013 .

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells

B. Barlogie, J. Epstein, F. van Rhee, 2014, Blood Cancer Journal.

Murine Models of Myeloma Bone Disease: The Importance of Choice

P. Croucher, J. Epstein, K. Vanderkerken, 2010 .

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

B. Barlogie, E. Anaissie, J. Epstein, 2013, Haematologica.

A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents.

H. Preisler, J. Epstein, 1983, European Journal of Cancer and Clinical Oncology.

Effects of cytosine arabinoside on DNA synthesis as predictor for acute myelocytic leukemia (AML) patients' response to chemotherapy.

H. Preisler, J. Epstein, 1981, European journal of cancer.

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

J. Crowley, B. Barlogie, J. Epstein, 2013, Leukemia.

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2018, Clinical Cancer Research.

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma

O. Stephens, B. Barlogie, E. Tian, 2015, Leukemia.

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2018, Blood Cancer Journal.

Myeloma-Derived Exosomes and Soluble Factors Suppress Natural Killer Cell Function

G. Morgan, F. Davies, Priyangi A. Malaviarachchi, 2016 .

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

B. Barlogie, G. Morgan, M. Zangari, 2016, Immunotherapy.

Functional Imaging Detects Residual Disease in MRD-Negative Multiple Myeloma Patients Who Subsequently Relapse

B. Barlogie, G. Morgan, M. Zangari, 2017 .

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

B. Barlogie, G. Morgan, M. Zangari, 2015 .

A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3

O. Stephens, B. Barlogie, A. Vangsted, 2016, British journal of haematology.

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

B. Barlogie, A. Dispenzieri, S. Rajkumar, 2015 .

MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma

B. Barlogie, J. Epstein, S. Yaccoby, 2013 .

Predictive Biomarkers and Personalized Medicine Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR 3 C 1

B. Barlogie, J. Shaughnessy, E. Anaissie, 2012 .

Growth and dormancy control of myeloma cells by mesenchymal stem cells.

I. Nookaew, M. Zangari, J. Epstein, 2023, Leukemia research.

myeloma therapy The syndecan-1 heparan sulfate proteoglycan is a viable target for

B. Barlogie, L. Suva, J. Epstein, 2013 .

Biological aspects of multiple myeloma.

B. Barlogie, J. Epstein, R. Hoover, 1995, Bailliere's clinical haematology.

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.

B. Barlogie, J. Shaughnessy, E. Anaissie, 2005 .

IP3, IP3 receptor, and cellular senescence

S. Goldstein, Li Sun, M. Zaidi, 2000 .

Myeloma Bone Disease

J. Epstein, R. Sanderson, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS)

Weida Tong, Huixiao Hong, Leming Shi, 2005, BMC Bioinformatics.

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression

B. Barlogie, J. Shaughnessy, E. Tian, 2015, Genes, chromosomes & cancer.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

Caleb K. Stein, B. Barlogie, G. Morgan, 2016, Blood Cancer Journal.

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

D. Campana, B. Barlogie, J. Shaughnessy, 2012, Haematologica.

Curing myeloma at last: defining criteria and providing the evidence.

B. Barlogie, G. Morgan, J. Epstein, 2014, Blood.

Characterization of Wnt/β‐catenin signalling in osteoclasts in multiple myeloma

B. Barlogie, Y. Qiang, J. Epstein, 2010, British journal of haematology.

Expanded Natural Killer (NK) Cells for Immunotherapy: Fresh and Made to Order

D. Campana, B. Barlogie, C. Rooney, 2012 .

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

B. Barlogie, J. Shaughnessy, E. Anaissie, 2008, Cancer.

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data

B. Barlogie, E. Anaissie, J. Epstein, 2013, Haematologica.

This information is current as Mitogen-Activated Protein Kinase p 38 Immature Dendritic Cells : Involvement of ofLipopolysaccharide on In Vitro Generation Novel and Detrimental Effects of

J. Epstein, Siqing Wang, J. Qian, 2003 .

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression

B. Barlogie, J. Shaughnessy, E. Tian, 2015, Genes, chromosomes & cancer.